General Atlantic, a global growth equity firm, led a $143m Series B round in CinCor Pharma, a clinical-stage biopharmaceutical company, with participation from Perceptive Advisors, BVF Partners, venBio Partners, Adage Capital Management, Omega Funds, Rock Springs Capital, RTW Investments, Lilly Asia Ventures, Sixty Degree Capital, Sofinnova Investments, Sofinnova Partners, 5AM Ventures and CinRx. "This financing will enable us to obtain the data that we hope will establish that aldosterone synthesis inhibition is a potent approach to lowering blood pressure in several patient groups, including individuals with hypertension demonstrated to be resistant to existing treatment options. In addition, it will enable us to continue to obtain data that may expand the potential utility of CIN-107 into other indications including primary aldosteronism and CKD. We welcome our new high-quality investors to CinCor and Jason to the Board," Marc de Garidel, CinCor CEO.